secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001104659-23-097730
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus Life Sciences furnishes September 2023 investor slide deck; no material new information disclosed
--------------------------------------------------------------------------------

- Slide deck posted on company website for investor use; no earnings, guidance, or corporate updates provided.
- Presentation reiterates mission to treat liver and pancreatic tumors through immunotherapy and drug delivery technology.
- No changes in financial position, operations, or management disclosed; filing is routine Regulation FD disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923097730/0001104659-23-097730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923097730/tm2325342d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-097730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer